NEWS
INVESTMENT IN RESEARCH
Novo Nordisk has entered into a research
collaboration with the University of Oxford
on focusing on Type 2 diabetes investing
£115m in new research centre over a
period of 10 years.
The partnership will enable scientists
from Novo Nordisk and University
of Oxford to collaborate to discover
innovative approaches for treating Type
2 diabetes. The Novo Nordisk Research
Centre Oxford will employ up to 100 Novo
Nordisk researchers, based in an Oxford
University research centre. The centre
will focus on innovation within early stage
research that has potential to substantially
impact future treatment of Type 2 diabetes
and its complications.
Chief Science Officer and Executive
Vice President of Novo Nordisk, Mads
Krogsgaard Thomsen commented on
the investment saying, "This collaboration
brings together some of the world's
sharpest minds in the field of diabetes
to seek new targets for therapeutic
innovation. It combines Novo Nordisk's
90 years' experience in developing
treatments for diabetes with the expertise
of world leading scientists from the
University of Oxford. Our vision is that
the unique combination of industrial and
academic know-how will eventually lead
to a new generation of treatments to
improve the lives of people with Type 2
diabetes."
The collaboration will actively seek
to encourage cross-fertilisation of ideas
between academic researchers from
the University of Oxford and researchers
employed by Novo Nordisk with funds to
sponsor the collaborative research.
Sir John Bell, Regius Professor of
Medicine, University of Oxford, added,
"We see the collaboration with Novo
Nordisk as an outstanding opportunity
to mix competence embedded at
our campus with Novo Nordisk's
groundbreaking research and results in
diabetes. This collaboration underlines
the importance of shared research and
cutting-edge science across boundaries.
Employees will have the opportunity for
daily interaction to share knowledge and
insights that will potentially produce new
medicines for people living with type 2
diabetes and its complications".
James D. Johnson, Professor, PhD,
has been appointed head of the Novo
Nordisk Research Centre Oxford.
VOLUNTEERS
NEEDED
T1DUK is looking to recruit participants
in a new exploration of the peripheral
immune system in subjects with
New Onset T1 Diabetes (NOT1D).
Volunteers can be male or female
aged between18-40 who have been
diagnosed with Type 1 Diabetes in the
last 6 weeks.
Type 1 Diabetes UK Immunotherapy
Consortium (T1D UK) was set up in 2015
with major funding from Diabetes UK and
JDRF to promote, develop and support
immunotherapy research in T1D. It is
due to establish and train a network of
15 Level 1 Research Sites strategically
distributed across the UK that will work
in partnership with the ADDRESS 2
recruitment infrastructure.
There are two main cores to T1D
UK, a clinical engagement and training
core (CET) led by Prof Colin Dayan from
Cardiff University, and a mechanistic core
with five specialist laboratories located
throughout the UK, led by Tim Tree from
Kings College, London.
The study's aim is to gain a better
understanding of the processes that may
lead to the immune system's destruction
of insulin-producing beta cells, which
help to control bloodsugar levels.
T1DUK is looking to recruit
participants in a new exploration of the
peripheral immune system in subjects
with New Onset T1 Diabetes (NOT1D).
Volunteers can be male or female
aged between18-40 who have been
diagnosed with Type 1 Diabetes in the
last 6 weeks.
To take part click this link:
www.type1diabetesresearch.org.uk